Home > Special Features

Special Features

29-Jan-2024	2023 Second Half Year Review
	Volatile Half for Australian Biotech Sector

21-Jul-2023	2023 First Half Year Review
	Capital Starts Return to Biotech Sector

18-Jan-2023	2022 Second Half Year Review
	Australian Biotechs Expected to Continue Recovery into 2023

20-Jul-2022	2022 First Half Year Review
	Worst Biotech Half on Record – Sector Down 41%

19-Jan-2022	December Quarter 2021
	Australian Biotech's on Acquisition Path

6-Oct-2021	September Quarter 2021
	Australian Biotech Attracts $1.9 Billion in Capital

13-Jul-2021	June Quarter 2021
	Biotech Stock Demand Settles in June Quart

1-Apr-2021	March Quarter 2021
	Biotech's Continue Strong Run on ASX

6-Jan-2021	December Quarter 2020
	Biotech Stocks Hold Steady in Dec Quarter

5-Oct-2020	September Quarter 2020
	Keen Interest Pushes Bioshares Index Higher

6-Jul-2020	June Quarter 2020
	Strong Demand for Biotech in June Quarter

6-Apr-2020	March Quarter 2020
	Biotech's Lose 27% in March Quarter

3-Jan-2020	December Quarter 2019
	Biotech Successes Drive Record Capital Inflows for December Quarter

30-Sep-2019	September Quarter 2019
	Another Winning Quarterforthe Bioshares Index

1-Jul-2019	June Quarter 2019
	Bioshares Index up 21% in June Quarter

8-Apr-2019	March Quarter 2019
	Stocks Surge, Funding Plummets

2-Jan-2019	December Quarter 2018
	The Difficult, Risky Business of Biotech

28-Sep-2018	September Quarter 2018
	Three Billion Dollar Companies Lead the Bioshares Index

29-Jun-2018	June Quarter 2019
	US Sales Underperformance Puts Brake on Bioshares Index

29-Mar-2018	March Quarter 2019
	M&A Action Keeps the Bioshares Index in Positive Territory

29-Dec-2017	December Quarter 2017
	Bioshares Index Rebounds – Posts 11% Gain

29-Sep-2017	September Quarter 2017
	Very Little Lustre for Biotechs in Q3 2017

30-Jun-2017	June Quarter 2017
	Bioshares Index Loses 14% in June Quarter

31-Mar-2017	March Quarter 2017
	Medical Cannabis Stocks Dominate Play in the March Quarter

2-Jan-2017	December Quarter 2016
	A Weak Quarter for Life Science Stocks

30-Sep-2016	September Quarter 2016
	Investors Pick Their Favourites – Bioshares Index Posts 15% Sept Qtr Gain

26-Sep-2014	Edition 570 - Invion Shows Escalating Dosing Approach Holds Up

19-Sep-2014	Edition 569 - FDA Committee Reviews Testosterone Replacement Therapies

12-Sep-2014	Edition 568 - Cogstate Signs Important Precision Recruitment Contract

5-Sep-2014	Edition 567 - Impedimed Gains Expanded Reimbursement Status for L-Dex

29-Aug-2014	Edition 566 - Forrest Capital Launches Alzheimer's Disease Drug Play

22-Aug-2014	Edition 565 - Bionomics Books Its First Profit

15-Aug-2014	Edition 564 - FitGenes IPO Profile

8-Aug-2014	Edition 563 - Invion’s Busy Months Ahead

1-Aug-2014	Edition 562 - Somnomed To Double Manufacturing Capacity

25-Jul-2014	Edition 561 - The 10th Bioshares Biotech Summit Cell Therapies Session

23-Jul-2014	Edition 560 - Reports From The 10th Bioshares Biotech Summit

11-Jul-2014	Edition 559 - Somnomed Builds Leading Position in Europe

4-Jul-2014	Edition 558 - Quarterly Review - June Quarter Slump for the Bioshares Index

27-Jun-2014	Edition 557 - Bionomics Surprises Market with US$20 Million Upfront Alzheimer's Disease Deal

20-Jun-2014	Edition 556 - US Life Science IPOs Roll On

13-Jun-2014	Edition 555 - Dimerix Bioscience IPO Profile

6-Jun-2014	Edition 554 - Orthocell IPO Profile

30-May-2014	Edition 553 - Benitec Biopharma Doses First Patient in Phase I/II HCV Trial

23-May-2014	Edition 552 - OBJ Gains From P&G Product Licence But Bodyguard Product Is The One To Watch

16-May-2014	Edition 551 - LBT Innovations Targets Second Product Launch for 2015

9-May-2014	Edition 550 - Specialised Therapeutics Australia Takes on pSivida’s Iluvien Eye Drug

2-May-2014	Edition 549 - Oncosil Medical Waits on Green Light to Start Pivotal Study

25-Apr-2014	Edition 548 - International Investors Extend Interest Into Private Australian Biotechs

23-Apr-2014	Edition 547S - Special Edition - FDA Panel Votes 14-0 Against QRxPharma’s Moxduo

11-Apr-2014	Edition 547 - Universal Biosensors: Signs Of A‘Hockey Stick’ Growth Curve Emerge With Service Fees

4-Apr-2014	Edition 546 - Quarterly Review - Bioshares Index Steady in March Quarter

28-Mar-2014	Edition 545 - LBT Innovations’ APAS: What Are The Benefits?

21-Mar-2014	Edition 544 - Bionomics Misses Primary Endpoint In Phase II Renal Cancer Study

14-Mar-2014	Edition 543 - RA Capital Builds Position In pSiVida With US$7M Investment

7-Mar-2014	Edition 542 - Calzada Receives FDA Approval for First Wound Healing Product

28-Feb-2014	Edition 541 - Somnomed – Building the Complete Oral Appliance Therapy Company

21-Feb-2014	Edition 540 - Prana Biotechnology Achieves Some Positive Signals in Phase II Huntington's Disease Trial

14-Feb-2014	Edition 539 - Rhinomed – Adoption Of The Turbine Underway

7-Feb-2014	Edition 538 - Innate Immunotherapeutics – Preclinical Studies Validate Clinical Mechanism of Action

31-Jan-2014	Edition 537 - Viralytics Cashes Up

24-Jan-2014	Edition 536 - Strong Quarter for Somnomed Signals Pivotal Year Ahead

2-Jan-2014	Edition 535 - Quarterly Review - Biotechs Ride Sentiment to Boost Cash Holdings

20-Dec-2013	Edition 534 - Admedus Gains Manufacturing Headstart

13-Dec-2013	Edition 533 - Benitec Files IND – Last Major Hurdle Before Clinical Studies Begin

6-Dec-2013	Edition 532 - Pharmaust’s PPL-1 – Will it Set a New Safety Benchmark for Cancer Drugs?

29-Nov-2013	Edition 531 - Sirtex Medical: Is $107 a Share Possible?

22-Nov-2013	Edition 530 - IPO Profiles: Dorsavi and Innate Immunotherapeutics

15-Nov-2013	Edition 529 - Viralytics Reports More Positive Data from Phase II Melanoma Study

8-Nov-2013	Edition 528 - Antisense Therapeutics Approaching Major Inflexion Point

1-Nov-2013	Edition 527 - Unexpected Bonus for Universal Biosensors

25-Oct-2013	Edition 526 - Imugene Acquires Biolife Takes Aim at the US$6 Billion Her2+ Cancer Market

18-Oct-2013	Edition 525 - US Biotech Boom Set to Infect Australia

10-Oct-2013	Edition 524 - Mesoblast Acquires Osiris’ ceMSC Assets

3-Oct-2013	Edition 523 - Quarterly Review - Biotech Stocks Power Ahead

27-Sep-2013	Edition 522 - Somnomed to Launch New Products in FY14 and Complete Trials to Support Compliance Claims

20-Sep-2013	Edition 521 - Perth Biotech Briefing

13-Sep-2013	Edition 520 - Biotech Bull Market Special Edition Bioshares Top 10 Picks

6-Sep-2013	Edition 519 - Invion – Three Phase II Readouts Approaching and No Cash Required

30-Aug-2013	Edition 518 - Mesoblast Updates Market on Phase III CHF Trial

23-Aug-2013	Edition 517 - Cogstate Results – Investing to Expand Markets and Applications

16-Aug-2013	Edition 516 - Sirtex Medical Nudges $100 Million in Sales; Retains Cash of $52 Million

9-Aug-2013	Edition 515 - The Oncosil Medical Plan – Follow Sirtex!

2-Aug-2013	Edition 514 - Tissue Therapies Effects Positive Reversal from European Regulators

26-Jul-2013	Edition 513 - The 9th Bioshares Biotech Summit Reports – Part 2

22-Jul-2013	Edition 512 - The 9th Bioshares Biotech Summit Reports – Part 1

12-Jul-2013	Edition 511 - The US Life Science IPO Window Blows Wide Open

5-Jul-2013	Edition 510 - LBT Innovations – Adds Another Productivity Tool to the Microbiology Lab

28-Jun-2013	Edition 509 - Quarterly Review - Bioshares Index Softens in June Quarter

21-Jun-2013	Edition 508 - FX Effects for Australian Biotechs

14-Jun-2013	Edition 507 - Somnomed – US Market Back on Track as Somnodent Shows Similar Health Outcome to CPAP Gold Standard

7-Jun-2013	Edition 506 - Universal Biosensors – An Outstanding Investment Proposition

31-May-2013	Edition 505 - Pharmaxis Restructures for Survival

24-May-2013	Edition 504 - Osprey Expands Product Portfolio

17-May-2013	Edition 503 - Synergistic Partnerships Support Cogstate's Rollout of Cognigram in Canada

10-May-2013	Edition 502 - Positive Clinical Trial Results from Calzada – Company to File 510(k)

3-May-2013	Edition 501 - Atcor Medical Posts Third Consecutive Positive Cash Flow Quarter

26-Apr-2013	Edition 500 - Five Hundred

19-Apr-2013	Edition 499 - Invion – Three Phase II Shots at Goal

12-Apr-2013	Edition 498 - Pharmaxis Waits on Bronchiectasis Phase III Results and FDA to Set Future Direction

28-Mar-2013	Edition 497 - Quarterly Review - Bioshares Index Treads Water in March Quarter

22-Mar-2013	Edition 496 - Reva’s ReZolve Stent to Ride the Abbott Absorb Wave

15-Mar-2013	Edition 495 - Entrepreneurs Return with Biolife Cancer Vaccine Play

8-Mar-2013	Edition 494 - Mesoblast Enters Agreement for Record Capital Raising for Australian Biotech Sector

1-Mar-2013	Edition 493 - Companies With Pivotal Events Ahead – Part 1

22-Feb-2013	Edition 492 - Revenue up 100% at Universal Biosensors

15-Feb-2013	Edition 491 - Nanosonics’ Trophon EPR: A "Transformational Product"

8-Feb-2013	Edition 490 - Another Signal from Forrest Capital that Biotech is Replacing Mining as a Destination for Speculative Capital

1-Feb-2013	Edition 489 - Pharmaxis – FDA Panel Rebuff Means Further CF Trial Likely for Bronchitol in US

25-Jan-2013	Edition 488 - Major Crossroads Ahead for Pharmaxis

18-Jan-2013	Edition 487 - QRxPharma – FDA to Hold Advisory Committee Meeting for MoxDuo IR

31-Dec-2012	Edition 486 - Quarterly Review - Small Cap Biotech Weakness Offset by Strong Growth in Large Cap Stocks in Dec Quarter

14-Dec-2012	Edition 485 - Somnomed Reinforces Global Distribution Networks through EU Acquisitions

7-Dec-2012	Edition 484 - Tissue Therapies – EMA Clearance the Final Sticking Point

30-Nov-2012	Edition 483 - Starpharma's Phase III BV Treatment Trial Fails to Meet Primary Endpoint

23-Nov-2012	Edition 482 - Somnomed AGM Report

16-Nov-2012	Edition 481 - Benitec’s Big Hepatitis C Play

9-Nov-2012	Edition 480 - Nanosonics AGM Report

2-Nov-2012	Edition 479 - The 2012 Bell Potter Life Sciences Conference

26-Oct-2012	Edition 478 - Clinical Trial Updates for Starpharma, Prima Biomed and Viralytics

19-Oct-2012	Edition 477 - Global Pharma Restructure Takes its Toll on Local Service Companies

12-Oct-2012	Edition 476 - Rumours of Takeover Circle Pharmaxis

28-Sep-2012	Edition 474 - Quarterly Review - Strong Gains in Sirtex Medical Drive Growth in the Bioshares Index

21-Sep-2012	Edition 473 - Universal Biosensors Enters Supply Agreement with Siemens

14-Sep-2012	Edition 472 - Tissue Therapies – A Matter of Patience

7-Sep-2012	Edition 471 - Profit Wrap – FY2012

31-Aug-2012	Edition 470 - Success for Bionomics' Partner Ironwood Pharmaceuticals

24-Aug-2012	Edition 469 - Mesoblast Powers Ahead With Clinical Programs

17-Aug-2012	Edition 468 - The Biota-Nabi Merger: Issues to Consider

10-Aug-2012	Edition 467 - Delay in Europe for Tissue Therapies’ VitroGro

3-Aug-2012	Edition 466 - Pharmaxis Receives PDUFA Date for Bronchitol

27-Jul-2012	Edition 465 - 2012 Bioshares Biotech Summit Report (Part 2 – Analysts Session)

24-Jul-2012	Edition 464 - 2012 Bioshares Biotech Summit Report (Part 1)

13-Jul-2012	Edition 463 - Alchemia's Audeo Oncology Files Registration Statement in Preparation for US IPO

6-Jul-2012	Edition 462 - Quarterly Review - A Stressful June Quarter for Biotech

29-Jun-2012	Edition 461 - FDA Delays QRxPharma’s MoxDuo IR

22-Jun-2012	Edition 460 - Mayne Pharma’s SUBACAP Approved in the UK

15-Jun-2012	Edition 459 - Biotech Investment Strategies for Handling European Financial Volatility

8-Jun-2012	Edition 458 - Pharmaxis Produces Like-For-Like CF Data with Vertex Drug Combo

1-Jun-2012	Edition 457 - Nanosonics – Sales Begin to Bud

25-May-2012	Edition 456 - Report – The 2012 Bell Potter Life Sciences Conference

18-May-2012	Edition 455 - Multiple Value Drivers Support Interest in Mesoblast’s Share Price

11-May-2012	Edition 454 - Mayne Pharma Group - Life After Doryx?

4-May-2012	Edition 453 - Tissue Therapies – Approval & Product Launch Approaching

27-Apr-2012	Edition 452 - Biota Plans Merger with Nasdaq-listed Nabi Biopharmaceuticals and ASX De-listing

20-Apr-2012	Edition 451 - Pharmaxis – Bronchitol Ready to Go!

14-Apr-2012	Edition 450 - Sirtex Sales Boom in the US

30-Mar-2012	Edition 449 - Quarterly Review - Investors Favour Biotech

23-Mar-2012	Edition 448 - Australian Biotechs Continue Charge To Market With Late Stage Clinical Assets

16-Mar-2012	Edition 447 - QRxPharma – Ability to Succesfully Launch Novel Pain Drug Now Clearly Visible

9-Mar-2012	Edition 446 - IPO Profile - Osprey Medical Inc

2-Mar-2012	Edition 445 - FY2012 Half Year Results Analysis

24-Feb-2012	Edition 444 - Sir-Spheres Consolidates its Position for Treating Primary and Secondary Liver Cancer

17-Feb-2012	Edition 443 - Cross-Border Listings Ramp Up With Surging US Biotech Sector Interest

10-Feb-2012	Edition 442 - Somnomed – Very Attractive Buying

3-Feb-2012	Edition 441 - Universal Biosensors – OneTouch Verio Launched in US; Sales Expected to Accelerate

27-Jan-2012	Edition 440 - Bionomics Signs Licensing Deal with Ironwood Pharmaceuticals

30-Dec-2011	Edition 439 - Quarterly Review - Investors Pour $630 Million into Sector as Biotech Prices Fall 24.4% for 2011

23-Dec-2011	Edition 438 - QRxPharma Cuts Creative Deal with Actavis for MoxDuo

16-Dec-2011	Edition 437 - Probiomics and Hunter Immunology to Merge via Public Offer

9-Dec-2011	Edition 436 - Positive Phase I Trial Results for Antisense Therapeutics’ Acromegaly Drug Candidate

2-Dec-2011	Edition 435 - Tissue Therapies Bypasses ‘The Pharmocracy’ – Appoints Contract Sales Teams in Europe

25-Nov-2011	Edition 434 - Capital Inflows Support Later Stage Biotechs

11-Nov-2011	Edition 433 - Clinuvel Pharmaceuticals – Prepares to File Scenesse for Approval

4-Nov-2011	Edition 432 - Financial Execution Risk for Biotechs – Can They Fund the Business Plan?

28-Oct-2011	Edition 431 - Clear Path to Market for Starpharma's BV Product

21-Oct-2011	Edition 430 - Pharmaxis – Bronchitol Success in Europe!

14-Oct-2011	Edition 429 - Quarterly Review - Bioshares Index Slides 14% in Sept Qtr

7-Oct-2011	Edition 428 - Biota Holdings – A Takeover Target?

30-Sep-2011	Edition 427 - Pharmaxis Argues Case For European Approval

23-Sep-2011	Edition 426 - Sunshine Heart – Initial Data from Feasibility Study Released

16-Sep-2011	Edition 425 - Mayne Pharma Group – All Eyes on Doryx But SUBACAP Asset Being Missed

9-Sep-2011	Edition 424 - UBI Strikes Second Major Commercial Deal

2-Sep-2011	Edition 423 - Somnomed Posts Healthy Growth in Unit Sales; Next Gen Product in the Wings

26-Aug-2011	Edition 422 - Antisense Therapeutics Moves Forward With Acromegaly Program

19-Aug-2011	Edition 421 - IPO Profile – GI Dynamics

12-Aug-2011	Edition 420 - Alchemia – Time to Temper Expectations as Authorised Generic Surfaces

5-Aug-2011	Edition 419 - Bionomics Phase II BNC105 Results – In Line With Expectations

29-Jul-2011	Edition 418 - Bioniche’s Three Turning Points

25-Jul-2011	Edition 417 - The 7th Bioshares Biotech Summit – Report

15-Jul-2011	Edition 416 - FDA Clears Generic Fondaparinux

8-Jul-2011	Edition 415 - Impressive Start for Sales of Axiron

1-Jul-2011	Edition 414 - Quarterly Review - Bioshares Index Falls 9% in June Quarter

24-Jun-2011	Edition 413 - Acrux – Growth in Testosterone Product Sales Indicate Strong Potential for Axiron

17-Jun-2011	Edition 412 - Clinical Trials Survey 2011

10-Jun-2011	Edition 411 - Bluechiip Lists on the ASX

3-Jun-2011	Edition 410 - Heightened Interest In Neuren

27-May-2011	Edition 409 - Southern Cross Equities Life Science Conference

20-May-2011	Edition 408 - Universal Biosensors – Prothrombin Time Test the One to Watch for 2011

13-May-2011	Edition 407 - Sunshine Heart’s C-Pulse Device – Expert Review

6-May-2011	Edition 406 - Cogstate JV Launches New Product Suite: Axon Potential

29-Apr-2011	Edition 405 - Somnomed – ‘Ready for Take-off’

15-Apr-2011	Edition 404 - Pharmaxis European Approval for Bronchitol – Strong Likelihood of Success

8-Apr-2011	Edition 403 - Viralytics Waits for IND Greenlight

1-Apr-2011	Edition 402 - Quarterly Review - Biotech Posts Solid Gains for 2011 First Quarter

25-Mar-2011	Edition 401 - Acrux – Axiron Launch Imminent & $100 Million to be Paid to Shareholders

18-Mar-2011	Edition 400 - Bioniche – The Urocidin Story

11-Mar-2011	Edition 399 - Sirtex Medical – Investing in Long Term Revenue Growth

4-Mar-2011	Edition 398 - QRxPharma – NDA Filing Expected in Coming Months

25-Feb-2011	Edition 397 - Bionomics Builds Intense Interest in BNC210

18-Feb-2011	Edition 396 - Cellestis – Delivering Sustained Growth

11-Feb-2011	Edition 395 - Success for Pharmaxis! Bronchitol Gains Australian Approval for the Treatment of Cystic Fibrosis

4-Feb-2011	Edition 394 - IPO Profile – BlueChiip

28-Jan-2011	Edition 393 - Biotech IPO Window: “Open”

14-Jan-2011	Edition 392 - The Bioshares Top 10 Picks for 2011

6-Jan-2011	Edition 391 - Quarterly Review - Transformational Deals Drive 20% Gain in Bioshares Index

17-Dec-2010	Edition 390 - Biotech Delivers in 2010... Momentum Set To Continue Into 2011

10-Dec-2010	Edition 389 - Mesoblast Stuns Market With US$350 Million Up-front Deal

3-Dec-2010	Edition 388 - Clinuvel – Scenesse Pricing in Italy Achieved at €32,250

26-Nov-2010	Edition 387 - Simply Magnificent Acrux!

19-Nov-2010	Edition 386 - Sunshine Heart to Raise up to $21 Million for Pivotal Year in 2011

12-Nov-2010	Edition 385 - Controversial Move by Start-up Australia Seeking Bionomics Sell-Off

5-Nov-2010	Edition 384 - Patrys Sets a New Pace for Natural Human Antibody Drug Development

29-Oct-2010	Edition 383 - Pharmaxis Investor Day – Insights on CF302 Phase III Trial Revealed

22-Oct-2010	Edition 382 - Cephalon Sets Up For Chemgenex Acquisition

15-Oct-2010	Edition 381 - As the AGM Season Begins – A Pause for Reflection

8-Oct-2010	Edition 380 - Pharmaxis Gains FDA Approval for Aridol

1-Oct-2010	Edition 379 - Quarterly Review - A Weak Result for the September Quarter

24-Sep-2010	Edition 378 - Phylogica – One Deal Away From a Re-Rating

17-Sep-2010	Edition 377 - Broadvector IPO Profile

10-Sep-2010	Edition 376 - In The Hands Of The Regulators

3-Sep-2010	Edition 375 - Biota Invests $25 Million in Phase II HRV Program

27-Aug-2010	Edition 374 - CogState Launches Axon Sports – Right Product, Right Time, Right Partner

20-Aug-2010	Edition 373 - Phylogica Signs Second Drug Discovery Collaboration With Major Partner

13-Aug-2010	Edition 372 - Are We Ready for the World's Biggest Paradigm Shift in Cancer Therapy?

6-Aug-2010	Edition 371 - Halcygen Pharmaceuticals – Mayne Pharma Integration Successful

30-Jul-2010	Edition 370 - Investment Round Table – 2010 Thredbo Biotech Summit

27-Jul-2010	Edition 369 - The 6th Bioshares 2010 Thredbo Biotech Summit - Event Coverage

16-Jul-2010	Edition 368 - Clinuvel Pharmaceuticals - Phase III Success Paves Way For European NDA

9-Jul-2010	Edition 367 - Heated Discussion at Avexa EGM

2-Jul-2010	Edition 366 - Quarterly Review - Rolling Backwards Down the Hill

25-Jun-2010	Edition 365 - Orphan Drugs – The New Way To Build Blockbuster Products

18-Jun-2010	Edition 364 - J&J Right Behind the UBI Developed Glucose Test Strip Platform

11-Jun-2010	Edition 363 - Viralytics Plans for Phase II with Cancer Killing Virus

4-Jun-2010	Edition 362 - Cardiologists Warm to Sunshine Heart’s Device

28-May-2010	Edition 361 - Patrys – Watch this Stock

21-May-2010	Edition 360 - Sirtex Medical Launches Aggressive Growth Plan

14-May-2010	Edition 359 - Avexa Winds Down; Mesoblast Consolidates Global Stem Cell Business

7-May-2010	Edition 358 - 2010 BIO State of the Industry Rep

30-Apr-2010	Edition 357 - Biota Holdings Share Price Comes Under Pressure With Volatile Relenza Sales

23-Apr-2010	Edition 356 - Living Cell Technologies Finally Makes Clinical Headway with Novel Diabetes Treatment

16-Apr-2010	Edition 355 - Bronchitol on Track for EU Approval

9-Apr-2010	Edition 354 - Quarterly Review - 12 Month Biotech Rally Ends

26-Mar-2010	Edition 353 - Chemgenex Pharmaceuticals – More Uncertainty Emerges

19-Mar-2010	Edition 352 - Acrux Signs Eli Lilly in Landmark Licensing Deal for Australian Biotech

12-Mar-2010	Edition 351 - Impedimed Gets US Category III Reimbursement

5-Mar-2010	Edition 350 - First Half 2010 Profit Wrap

26-Feb-2010	Edition 349 - Sirtex Medical – A Quietly Impressive Result

19-Feb-2010	Edition 348 - Biota Accelerates R&D

12-Feb-2010	Edition 347 - Clinuvel Pharmaceuticals – EPP A Clear First Market For Afamelanotide

5-Feb-2010	Edition 346 - Succesful Completion of Current Business Plan Will Set Up More Ambitious Phase for Bionomics

29-Jan-2010	Edition 345 - Strong Outlook Maintained for 2010

22-Jan-2010	Edition 344 - Pharmaxis Capitalises on Strong Scrip & Small Cap Biotech Financial Stress

1-Jan-2010	Edition 343 - Quarter Review - 2009 – A Comeback Year for Biotech

20-Dec-2009	Edition 342 - Stock Picks - 2010

11-Dec-2009	Edition 341 - ChemGenex Strikes $137 Million Deal for Omacetaxine

4-Dec-2009	Edition 340 - Mesoblast AGM Report

27-Nov-2009	Edition 339 - Impedimed AGM Report

20-Nov-2009	Edition 338 - The Danish Connection

13-Nov-2009	Edition 337 - Starpharma Seeks New Product Opportunity for Vivagel

6-Nov-2009	Edition 336 - Pharmaxis Files Bronchitol For European Approval…Acrux Appoints Commercial Advisor…Biotech Bull Run Continues

30-Oct-2009	Edition 335 - Sirtex Adds Third Manufacturing Facility As Global Rollout Of Sir-Sphere Product Continues

23-Oct-2009	Edition 334 - Strong Growth For Revenue Generating Biotechs While Currency Headwinds Stiffen

16-Oct-2009	Edition 333 - Wilson HTM Life Sciences Conference Report

9-Oct-2009	Edition 332 - Cytopia to Merge with YM Biosciences

2-Oct-2009	Edition 331 - Quarterly Review - Strong Support for Biotech Stocks Continues Through the September Quarter

25-Sep-2009	Edition 330 - Halcygen Up-Sizes With Strategic Acquisition Of Mayne Pharma Business

18-Sep-2009	Edition 329 - Australian Cancer Stocks Review

11-Sep-2009	Edition 328 - Gates Open For Biotech Stocks

4-Sep-2009	Edition 327 - Peplin To Be Acquired For $348 Million

1-Sep-2009	Edition 326 - Thredbo Biotech Summit 2009 Wrap

21-Aug-2009	Edition 325 - Strong Profit Performance From Biotechs

14-Aug-2009	Edition 324 - A Vindication for the Biota Business Model

7-Aug-2009	Edition 323 - Pharmaxis – Still On Track To Become Australia’s Most Successful Drug Development Business

31-Jul-2009	Edition 322 - Mesoblast – An Australia First Strategy

24-Jul-2009	Edition 321 - Hexima – To Seize Early Position In Nascent Multi Billion Dollar Biotech Seed Industry

17-Jul-2009	Edition 320 - Pharmaxis And ChemGenex De-list From Nasdaq

10-Jul-2009	Edition 319 - Sirtex Medical Flags Strong FY2009 Results

3-Jul-2009	Edition 318 - Quarterly Review - Strong Gains By Tier-1 Stocks Continues For Second Quarter

26-Jun-2009	Edition 317 - CathRx To Raise Funds, At A Price

19-Jun-2009	Edition 316 - Quantiferon Foundation Now Well Secured For Cellestis

12-Jun-2009	Edition 315 - ChemGenex Sets Target for EU Partner in 2009

5-Jun-2009	Edition 314 - Capital Begins to Flow Back into Biotech

29-May-2009	Edition 313 - Burrill's BIO 2009 Biotech State-of-the-Industry Address

22-May-2009	Edition 312 - Positive Results for Peplin’s Phase III Actinic Keratoses Trial

15-May-2009	Edition 311 - Stellar Performance by Leading Australian Biotech Stocks for Start of 2009

8-May-2009	Edition 310 - Excellent Result For Pharmaxis Phase III Cystic Fibrosis Trial

1-May-2009	Edition 309 - How Many Millions Of Lives Will These Three Australians Save?

24-Apr-2009	Edition 308 - Prima Biomed Back in the Spotlight

17-Apr-2009	Edition 307 - Late Stage Biotechs Attract Strong Investor Interest

3-Apr-2009	Edition 306 - A Gain For The Quarter But Funding For Biotech Looks Bleak

27-Mar-2009	Edition 305 - A Model Emerges on How to Build Successful Diagnostic Companies

20-Mar-2009	Edition 304 - Battle for Cash Assets in Non-Performing Biotechs not Exclusive to Australia

13-Mar-2009	Edition 302 - Alchemia's Partner Files ANDA As A Share Market Rally Starts

27-Feb-2009	Edition 301 - Cephalon Takes Cheap Shot at Arana Therapeutics

20-Feb-2009	Edition 300 - Strong Profit Season Underway

13-Feb-2009	Edition 299 - All Clear For Nanosonics Market Launch

6-Feb-2009	Edition 298 - Imugene – Another Success Story For Australian Biotech

30-Jan-2009	Edition 297 - Healthcare Earners Shine Through While Credit Crisis Starts to Take its Toll on Cash Burning Biotechs

23-Jan-2009	Edition 296 - A Few Positives Launch Biotech Into 2009

2-Jan-2009	Edition 295 - Quarterly Review - Biotech Sector Contraction Ahead in 2009

19-Dec-2008	Edition 294 - A Tale of Two Cities for Australian Biotech

12-Dec-2008	Edition 293 - The Australian Biotech Sector – Rationalisation Begins

5-Dec-2008	Edition 292 - QRxPharma and Pain Drugs – Niche Opportunities or Major Markets?

28-Nov-2008	Edition 291 - The Global Financial Crisis and the Future of Australian Biotech

21-Nov-2008	Edition 290 - Biota Holdings – A Sustainable Business Established

14-Nov-2008	Edition 289 - Universal Biosensors Forecasts Strong Sales For CY2009

7-Nov-2008	Edition 288 - Osiris Therapeutics Strikes US$130 Million Deal With Genzyme... Positive News for Mesoblast

31-Oct-2008	Edition 287 - Apollo Life Sciences Appoints Administrators ... Alchemia Sacks 30 Staff…Phenomix Strikes US$75 Million Upfront Partnering Deal

24-Oct-2008	Edition 286 - Cellestis Hits the ‘Hockey Stick’ Sweet Spot

17-Oct-2008	Edition 285 - Wilson HTM Conference Coverage – 'Show Me The Money'

10-Oct-2008	Edition 284 - Safe Haven Stocks in the Life Sciences Sector

3-Oct-2008	Edition 283 - Quarterly Review - Hard Times Ahead

26-Sep-2008	Edition 282 - Labtech Systems – A Success Story

19-Sep-2008	Edition 281 - Major Clinical Endpoint Approaching for Pharmaxis

12-Sep-2008	Edition 280 - Starpharma Secures Major Licensing Deal

5-Sep-2008	Edition 279 - Stem Cell Smarts About To Pay Off

29-Aug-2008	Edition 278 - Notes and Highlights from Selected 2008 Annual Reports

22-Aug-2008	Edition 277 - VCs Take Control of Peplin Inc

15-Aug-2008	Edition 276 - Acrux – Commercialisation Forges Ahead

8-Aug-2008	Edition 275 - Peplin Valuation Highlights Market Pricing Disparity

1-Aug-2008	Edition 274 - Intriguing Results for Neurodiscovery’s Pain Compound NSL-043

29-Jul-2008	Edition 273 - Roche Lands in Thredbo – Will it Trigger a Biotech Avalanche?

18-Jul-2008	Edition 272 - Credit Crisis Forces Rationality Into Biotech Sector

11-Jul-2008	Edition 271 - A Survey of Recent Life Science Acquisitions

4-Jul-2008	Edition 270 - Another Weak Quarter – Bioshares Index Falls 14.6%

27-Jun-2008	Edition 269 - 2009 Takeover Targets

20-Jun-2008	Edition 268 - Mesoblast – Strong Progress Continues

13-Jun-2008	Edition 267 - ASCO 2008 – Progress in Lung Cancer Treatments

6-Jun-2008	Edition 266 - The Evolution of Genetic Technologies

30-May-2008	Edition 265 - Japanese Pharma Goes Shopping

23-May-2008	Edition 264 - Commercial Ready Program Axed – What it Means for Biotech

16-May-2008	Edition 263 - Hexima - A Compelling Long Term Ag-Biotech Play

9-May-2008	Edition 262 - NIH Study Supports Impedimed’s Diagnostic Technology

2-May-2008	Edition 261 - The Potential for Alchemia's Fondaparinux

25-Apr-2008	Edition 260 - Clinical Trials Survey 2008

18-Apr-2008	Edition 259 - Profitable Cellestis Now One to Watch

11-Apr-2008	Edition 258 - Biotech Investment Activity To Be Driven By Demand for Acquisition Targets

4-Apr-2008	Edition 257 - Positive Sector Progress At Odds With Wider Market Chaos and Disaster

28-Mar-2008	Edition 256 - IDT Begins Next Phase With Strong Growth Prospects Ahead

14-Mar-2008	Edition 255 - Clinuvel Pharmaceuticals Successfully Changes Course with Regulators

7-Mar-2008	Edition 254 - Universal Biosensors – A Standout Pick In Any Market

29-Feb-2008	Edition 253 - Prana Biotechnology PBT-2 Trial Results Continues Run Of Positive Phase II Studies

22-Feb-2008	Edition 252 - Stockbroker & Investment Bank Performance 2007

15-Feb-2008	Edition 251 - Antisense Therapeutics Lands MS Licensing Deal With Teva

8-Feb-2008	Edition 250 - So Few Acquisitions for Australian Biotech

1-Feb-2008	Edition 249 - December Quarter Cash-Survival Analysis

25-Jan-2008	Edition 248 - The Great Big Biotech Stock Sale

18-Jan-2008	Edition 247 - The Year Ahead in Biotech 2008

19-Dec-2007	Edition 246 - The Year Ahead in Biotech 2008

14-Dec-2007	Edition 245 - More Positive Results Boost Peplin's PEP005

7-Dec-2007	Edition 244 - Class of '99 Steps Up to the Plate

30-Nov-2007	Edition 243 - IPO Profile: Advanced Surgical Design and Manufacture

23-Nov-2007	Edition 242 - Biotech's Phase III Leaders... Taking Stock

16-Nov-2007	Edition 241 - With Three Phase II Trials Planned, Cytopia Offers Exceptional Value

9-Nov-2007	Edition 240 - September Quarter Cash Survival Analysis

2-Nov-2007	Edition 239 - Efficient Restructuring and Placement of Biotech Assets Continues

26-Oct-2007	Edition 238 - Ventracor... Success Now Within Reach

19-Oct-2007	Edition 237 - Wilson HTM Conference: "Tapping into International Markets"

12-Oct-2007	Edition 236 - Stem Cell Sciences - Positioning for Global Stem Cell Growth

5-Oct-2007	Edition 235 - Biotech Stocks Hit By Global Volatility (Quarterly Review)

28-Sep-2007	Edition 234 - BMS Acquires Adnexus; Demand for Biologics Companies Remains Strong

21-Sep-2007	Edition 233 - Bypassing the Technical Risk - Super Generics

14-Sep-2007	Edition 232 - Reducing Technical and Investment Risk in Biotech

7-Sep-2007	Edition 231 - Positive Signs for US Biotech IPO Market

31-Aug-2007	Edition 230 - Pharmaxis Reports Positive Phase III Results for Bronchitol

24-Aug-2007	Edition 229 - Gardasil Boosts CSL's Bottom Line; Long-term Strategy Needs Action

17-Aug-2007	Edition 228 - Market Correction Sees Biotech Stocks Heavily Oversold; Sector on Cusp of Golden Period

10-Aug-2007	Edition 227 - A Blockbuster Week for Australian Biotech

3-Aug-2007	Edition 226 - Halcygen Pharmaceuticals - A Super Generics Play

13-Jul-2007	Edition 224 - A Stellar Listing for Patrys

6-Jul-2007	Edition 223 - Record Capital Inflow Dominates June Quarter Activity

29-Jun-2007	Edition 222 - Biotech Capital Invests $2M in Sensear

22-Jun-2007	Edition 221 - Ventracor Gets Sales Traction Through Major US Studies

15-Jun-2007	Edition 220 - Universal Biosensors - Will it Disrupt the IVD Industry?

8-Jun-2007	Edition 219 - Starpharma - Has it found the 'Holy Grail' for siRNA Drug Developers?

1-Jun-2007	Edition 218 - Time to Consider Vegenics as the "Main Game" at Circadian

25-May-2007	Edition 217 - Analysis: Stockbroker & Investment Bank Performance 2006

18-May-2007	Edition 216 - IPO Preview - QRxPharma Ltd

11-May-2007	Edition 215 - Third M&A Deal in 12 Months as Peptech Moves Up The Biotech Food Chain

4-May-2007	Edition 214 - Proteome Systems Effects Turnaround and Signs Deal with Minerva Healthcare

27-Apr-2007	Edition 213 - Relenza Royalty Stream Gains Traction for Biota

20-Apr-2007	Edition 212 - Antisoma-Novartis Deal Validates Programs at Bionomics and Cytopia

13-Apr-2007	Edition 211 - Biotech Sector Maintains Positive Gains

30-Mar-2007	Edition 210 - Prima Biomed's Fortunes Change as Dendreon Soars to US$1B Market Cap

23-Mar-2007	Edition 209 - Biodiem - An Attractive Value Proposition

16-Mar-2007	Edition 208 - Clinical Trials Survey 2007

9-Mar-2007	Edition 207 - 22 Million Reasons for Cytopia to Hit Milestones in 2007

2-Mar-2007	Edition 206 - Acrux Signs With Organon - More Deals Expected

23-Feb-2007	Edition 205 - Australian Biotechs Renegotiate License Arrangements

16-Feb-2007	Edition 204 - Australian Biotechs Quick to Move on Drug Repositioning Trend

9-Feb-2007	Edition 203 - Private Equity Circles Australian Biotech

2-Feb-2007	Edition 202 - Alchemia's Share Price Surges

26-Jan-2007	Edition 201 - Universal Biosensors Set to Succeed

19-Jan-2007	Edition 200 - An Encouraging Start to 2007

12-Jan-2007	Edition 199 - Biotech Sector Finds Favour With Investors

22-Dec-2006	Edition 198 - The Best of Biotech in 2006

15-Dec-2006	Edition 197 - Progen Releases Preliminary Data from PI-88 Liver Cancer Trial

8-Dec-2006	Edition 196 - Peptech Makes 5 Fold Return on Domantis Investment

1-Dec-2006	Edition 195 - Pivotal Milestones Approaching For Progen With Four Shots On Goal

24-Nov-2006	Edition 194 - Offshore Sale of Australian Biotech Continues

17-Nov-2006	Edition 193 - International Funds Target Australian Biotech Assets

10-Nov-2006	Edition 192 - Universal Biosensors

3-Nov-2006	Edition 191 - Acquisition of Sirna for US$1.1B May Signal Turning Point in Biotech Cycle

13-Oct-2006	Edition 188 - Bioshares 20 Index Posts Strong Gains

6-Oct-2006	Edition 187 - Biotech Sector Hits Bottom; Strong Inflow of Funds Continues

29-Sep-2006	Edition 186 - Peptech Aims High

22-Sep-2006	Edition 185 - Consolidation Signals Value for Biotech Investors

15-Sep-2006	Edition 184 - Biotech Sector's Cash Resources Total $960 Million

8-Sep-2006	Edition 183 - CyGenics Focuses on Cord Blood Banking Business

1-Sep-2006	Edition 182 - Biodiem Partners LAIV with the US Centers for Disease Control (CDC)

25-Aug-2006	Edition 181 - Avastra Transformation in Progress; Consolidation of US Sleep Centres Set To Begin

18-Aug-2006	Edition 180 - M&A in Australian Biotech Sector in Full Swing

11-Aug-2006	Edition 179 - Alchemia - Fundamentally a High Quality Stock; Use Price Weakness to Increase Exposure

4-Aug-2006	Edition 178 - Neuren Pharmaceuticals - Developing Broad Clinical Program; But Why the Discount?

28-Jul-2006	Edition 177 - Clinical Cell Culture - Now for the Hard Yards

14-Jul-2006	Edition 175 - June Quarter Biotech Slide Ends

7-Jul-2006	Edition 174 - Biotech Sector Oversold as Sector Falls by 18% in June Quarter

30-Jun-2006	Edition 173 - Progen Industries and Agenix Strengthen Data Packages for Licensing

23-Jun-2006	Edition 172 - Tax Loss Selling Contributes to Strong Price Falls in Biotechs

16-Jun-2006	Edition 171 - Avexa Approaching Crucial Milestone

9-Jun-2006	Edition 170 - Cytopia Partners JAK-3 Program with Novartis

2-Jun-2006	Edition 169 - Tier-1 Biotechs: Which Companies are Leading the Way?

26-May-2006	Edition 168F - US Biotech IPOs Back on the Agenda